Physician profile
John Smiley
NPI 1316089147
$12,847.07
in general payments reported to CMS, 2019-2025
50 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,406 · 2020: $421 · 2021: $1,582 · 2022: $1,844 · 2023: $2,509 · 2024: $2,768 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,594.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,177.09 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,006.52 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $871.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $832.40 | 2019-2025 | |
| Amgen INC. | $661.23 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $612.90 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $605.84 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $513.89 | 2020-2025 | Freestyle Libre, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $485.21 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $475.66 | 2019-2024 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $462.68 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $437.76 | 2019-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $435.87 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $400.04 | 2019-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $383.64 | 2019-2025 | Zoryve, Livalo, Seglentis |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Smiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.